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Integral membrane proteins play key biological roles in cell signaling, transport, and pathogen invasion. However, quantitative
clinical assays for this critical class of proteins remain elusive and are generally limited to serum-soluble extracellular fragments.
Furthermore, classic proteomic approaches to membrane protein analysis typically involve proteolytic digestion of the soluble
pieces, resulting in separation of intra- and extracellular segments and significant informational loss. In this paper, we describe the
development of a new method for the quantitative extraction of intact integral membrane proteins (including GPCRs) from solid
metastatic ovarian tumors using pressure cycling technology in combination with a new (ProteoSolve-TD) buffer system. This
new extraction buffer is compatible with immunoaffinity methods (e.g., ELISA and immunoaffinity chromatography), as well as
conventional proteomic techniques (e.g., 2D gels, western blots). We demonstrate near quantitative recovery of membrane proteins
EDG2, EDG4, FASLG, KDR, and LAMP-3 by western blots. We have also adapted commercial ELISAs for serum-soluble membrane
protein fragments (e.g., sVEGFR2) to measure the tissue titers of their transmembrane progenitors. Finally, we demonstrate the
compatibility of the new buffers with immunoaffinity enrichment/mass spectrometric characterization of tissue proteins.
1. Introduction
Integral membrane proteins, particularly G-protein-coupled
receptors (GPCRs), are the biological targets for half of all
the small molecule pharmaceuticals on the market today
[1–3]. Membrane transport proteins, such as P-glycoprotein
and related efflux pumps, are thought to impart chemother-
apy agent resistance by transporting the drugs from the
cytoplasm faster than they can diffuse back, thus lowering
the effective drug concentrations at the site of action [4].
Even the common cold (rhinovirus) invades the cell by first
binding to specific cell surface proteins [5–7], at least some
of which are thought to involve glycosylated and sialylated
extracelluar domain recognition sites [7, 8]. Clearly, integral
membrane proteins play key biological roles in cell signaling,
transport, and pathogen invasion. As such, membrane
proteins also play key clinical roles in drug efficacy and
resistance and should have a larger role in clinical diagnostics
and personalized medicine. However, quantitative clinical
assays (e.g., immunosorbent assays) for this important class
of proteins remain elusive and are generally limited to
serum-soluble extracellular fragments. Many serum markers
for cancer detection and treatment monitoring—such as
CA-125 (a serum-soluble fragment of mucin-16 approved
for recurrence monitoring of ovarian cancer), CA 15-3 (a
serum-soluble fragment of mucin-1 approved for recurrence
monitoring of breast cancer), sVEGFR (a serum-soluble
fragment of the vascular endothelial growth factor receptor
that is implicated as a prognostic marker in lung cancer) [9],
and sEGFR (a serum-soluble fragment of endothelial growth
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factor receptor that is implicated as a theranostic marker for
trastuzumab treatment in breast cancer) [10]—are currently
only accessible for clinical assays once extracellular fragments
are shed from the tumor cell membranes into the circulatory
system. Other membrane protein biomarkers—such as HER-
2/neu (an oncogenic growth factor receptor approved for
use in herceptin therapy guidance) [11] and the estrogen
receptor (an indicator for hormonal therapy in breast cancer)
[12]—are currently only accessible through gene-based
assays. Yet, genetic assays are unable to detect potentially
clinically relevant posttranslational modifications, such as
glycosylation, phosphorylation, acetylation, ubiquitination,
and editing. Furthermore, as has been well established for
more than a decade, measurements of mRNA levels, which
are produced transiently, do not correlate well to protein
levels, which accumulate over time [13, 14].
1.1. Membrane Protein Recovery and Purification. Classically,
detergents are used to extract membrane proteins from
biological membranes. Detergents also mediate membrane
protein solubility in aqueous solutions, which is a prereq-
uisite for further protein purification [15]. The surfactant
concentrations required to keep most membrane proteins in
aqueous solution also typically denature immunoglobulins,
precluding their use for immunoaffinity purification and
enrichment. Therefore, purification of membrane proteins is
often very tedious and is made more so because surfactants
can only partially mimic the lipid bilayer environment of
the protein in nature [16]. Thus, many membrane proteins
no longer retain their native biological conformations or
activities in surfactant solutions [17], except in isolated
cases [18]. Furthermore, not all proteins can be recovered
efficiently with the same surfactant. Mitic et al. showed
how the recovery of claudin-4 (with four transmembrane
sequences) from insect cell cultures failed to consistently
track total protein recovery over 37 different surfactants
tested, ranging from 0 to 169% of the sodium dodecyl sulfate
(SDS) control [19]. Surfactants also create limitations on
further proteomic analysis of membrane proteins, since sub-
sequent polyacrylamide gel electrophoresis of the recovered
proteins generally requires SDS, or other ionic surfactants
such as perfluorooctanoic acid [20]. With the exception of
newer acid-cleavable forms [21], surfactants can produce
ionization problems for mass spectrometric analyses, except
at very low concentrations [22, 23], which are too low to
support solubility of membrane proteins. Surfactants also
bind to surfaces, significantly altering the behavior of liquid
chromatographic media [24].
Because of the problems surfactants pose in chromato-
graphic and mass spectrometric proteomic analyses, several
membrane protein extraction schemes have been reported
based on chaotropic agents and organic solvents. Jacks et al.
report a 4 : 1 : 1 mixture of ethanol : acetonitrile : water as
being useful for recovering membrane proteins of mitochon-
drial and spherosomal origin in a system that is optically
transparent in the range of 200–700 nm [25]. The lower
end of this optical range is particularly useful for studying
protein structure by circular dichroism or quantification
by absorbance. Zhang et al. report on the use of aqueous
methanol, trifluoroethanol, and aqueous urea for the extrac-
tion of membrane proteins from red blood cells, finding that
each solvent system liberated different membrane proteins
[26]. Cordwell has advocated the use of a series of potent
chaotropic agents and detergents (increasing progressively
in strength) for protein extraction and fractionation, ending
with thiourea and amidosulfobetaine-14 [27]. He applied
this method to Gram-negative bacteria, cultured mammalian
cells, and heart tissue.
In all these cases, the more readily soluble proteins
are generally recovered first from the patient sample in
standard aqueous buffers from which they can be more
readily purified and assayed since all the solvents, detergents,
and chaotropic agents necessary to recover and solubilize
the integral membrane proteins are incompatible with the
downstream separation and purification schemes. Therefore,
the only applicable immunoaffinity technique that can be
used on most membrane proteins after surfactant extraction
is western blotting [28], which has only been sparing applied
in clinical settings (e.g., early human immunodeficiency
virus testing [29], early bovine spongiform encephalopathy
testing [30], and Lyme disease [31]). Even these were quickly
replaced when more robust nucleic acid or enzyme-linked
immunosorbent assay (ELISA) alternatives became available.
1.2. Proteolysis of Intra- and Extracellular Domains. Another
classic proteomic approach to membrane protein analysis
involves digestion of the generally soluble intra- and extracel-
lular domains from the generally insoluble transmembrane
regions. Nühse et al. used this approach in combination with
immobilized metal ion affinity chromatography (IMAC) to
study the phosphopeptides resulting from trypsin treatment
of the plasma membrane fraction isolated from cultured
Arabidopsis cells [32]. However, membrane proteins can
be refractory to digestion, particularly to trypsin, and
nonspecific digestion enzymes (e.g., pepsin and elastase)
are more commonly employed for this purpose [33]. The
challenge, therefore, is to control the degree of digestion
so that optimal recoveries are obtained. The resulting
mixtures of partially digested peptides limit detection of
the subsequent peptides by distributing the available signal
over more distinct, but related, mass spectrometric species.
Furthermore, this approach is generally only suited for
global proteomic analysis by liquid chromatography and
mass spectrometry since the resultant peptides are often not
immunologically active and mixtures of peptides are created
from all the membrane proteins found in the sample (both
diagnostic and nondiagnostic).
With the exception of qualitative immunohistochem-
istry, clinical exploitation of integral membrane proteins has
heretofore been limited by our ability to recover these pro-
teins in a form suitable for quantitative immunoassays and
rapid proteomic characterization. In this paper, we describe a
new approach for the combined quantitative recovery of both
cytosolic and integral membrane proteins in a buffer system
immediately suitable for direct use in immunosorbent assays
and subsequent mass spectrometric analyses. This approach
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uses the commercial ProteoSolve-TD1 and -TD2 extraction
buffers, developed in our laboratory and commercialized
by Pressure Biosciences (PBI), in combination with PBI’s
pressure cycling technology (PCT). This new approach is
demonstrated by extraction and analysis of several different
biomarker proteins from fresh frozen human metastatic
ovarian tumor tissues.
2. Material and Methods
2.1. Tissue Preparation and Protein Extraction. Fresh frozen
samples of metastatic ovarian tumors (surgically isolated
from the omentum of several different individuals) were
purchased from Bio-Options (Fullerton, CA). All samples
were reported to have been obtained from surgical resections
of stages III and IV ovarian cancer patients. The frozen tumor
samples were finely diced and mixed prior to extraction to
provide better sample homogeneity.
2.2. Cryogenic Grinding. Diced tumor tissue (200 mg) was
weighed into an aluminum weigh boat, precooled over dry
ice, to keep the samples frozen during processing. A mortar
and pestle were precooled by addition of liquid N2 until
a permanent lake of liquid N2 could be maintained in the
mortar. The tissue sample was added to the lake of liquid N2
and cryogenically ground under liquid N2 to a fine powder
(about the consistency of corn starch). Additional liquid
N2 was added as necessary. After grinding, the liquid N2
was allowed to evaporate, and the frozen tissue along with
any frozen condensate was transferred to a PULSE tube (an
integral part of the Barocycler device), which was precooled
in a bed of dry ice.
2.3. Extraction Buffers. Three different buffer systems were
used to extract proteins from the ground tumor tissue
samples. The control extraction buffer, adapted from Song
et al. for the homogenization of liver tissue for subse-
quent protein recovery and analysis, consisted of 20 mM
HEPES adjusted to pH 7.5 with NaOH [34]. This buffer
also forms the basis of the ProteoSolve-TD1 extraction
buffer (Pressure Biosciences, South Easton, MA), which
contains additional agents for membrane protein extraction
and stabilization. The ProteoSolve-TD2 extraction buffer
(Pressure Biosciences) was subsequently formulated with
additional agents to stabilize the ground tissue dispersion
during Barocycler operation, improving the reproducibility
of protein extraction between samples. All these buffers
were formulated to be compatible with subsequent pro-
tein labeling chemistries (e.g., aldehyde Schiff-base, N-
hydroxysuccinimide, or iodoacetamide) to facilitate quanti-
tative stable isotope work, such as isotope-coded affinity tags
(ICATs) [35], isobaric tags for relative and absolute quanti-
tation (iTRAQ) [36], and mass defect (isotope-differentiated
binding energy shift tags, IDBEST) [37].
2.4. Barocycler Extraction. The NEP2320 Barocycler (Pres-
sure Biosciences) was precooled with a circulating water bath
to 4◦C prior to use. All extraction buffers were refrigerated
(0–4◦C) overnight prior to use and used cold. Commercial
protease and phosphatase inhibitor cocktails (P8340, P5726,
and P2850, Sigma Aldrich, St. Louis, MO) were added to
each buffer according to package directions immediately
prior to use. PULSE tubes were loaded according to the
manufacturer’s instructions using 1.3 mL of the appropriate
buffer in each tube. The tubes were immediately processed
in the Barocycler (20 cycles from 0 to 35,000 psi for 20 sec on
each cycle).
The resulting extracts were viscous and were treated with
25 μL of micrococcal nuclease from Staphylococcus aureus
(New England Biolabs, Ipswich, MA) reconstituted at 1,000
units per mL per the manufacturer’s instructions, for 15 min
on ice. The resulting extract was recovered with a transfer
pipette and placed in a 2 mL microfuge tube along with any
residual pellet. The pellets with HEPES and TD1 extraction
buffers appeared as soft sticky disks generally pressed against
the center frit of the PULSE tube. Significantly less pellet
was formed in the TD2 extraction buffer, and the TD2
postextraction pellet proved to be very friable.
Insoluble materials were recovered from each extract
by centrifugation (13,000×g for 15 minutes at 4◦C). The
clarified extracts were recovered by aspiration to a second
microfuge tube. The pellets were resuspended in 1 mL of TD1
buffer by passing them through a 21-gauge syringe needle
several times to disperse the pellet. Because the pellets were
not washed, they contain some residual soluble protein. Both
the pellets and clarified extracts were stored in aliquots at
−80◦C prior to use.
2.5. 2-D Gel Electrophoresis. Aliquots (45 μL) of both the
HEPES- and TD1-clarified extracts were diluted into 365 μL
of ProteoSolve-IEF buffer (Pressure BioSciences, Inc.). First
dimension separation was carried out with 200 μL of each
diluted extract on the computer-controlled IsoelectrIQ2 IEF
apparatus (Proteome Systems, Ltd. Sydney, AU) using 11 cm,
pH 3–10 ReadyStrip IPG strips (Bio-Rad Laboratories, Inc.,
Hercules, CA). Separation was programmed with current
limited to 50 μA/strip in two steps: twelve hours on a concave
voltage ramp set to start at 100 V and end at 10,000 V,
followed by a constant voltage for 8 hours at 10,000 V. The
strips were removed at 90 kV-h. The second dimension was
performed on Criterion 8–16% polyacrylamide Tris-HCl
precast gels in a Dodeca Cell (both from Bio-Rad Labora-
tories), equipped with the Thermo-EC 570–90 power supply
at constant current of 60 mA/gel for 2 h. Gels were fixed and
stained with a ProteomIQ Blue Colloidal Coomassie gel stain
as described previously [38]. Gel images were acquired on a
UMAX PowerLook III flatbed scanner as 48-bit color TIFF
files and converted to 16-bit grayscale using ImageJ software
(NIH). Image analysis was performed using Ludesi REDFIN
3 software (Ludesi AB, Malmö, Sweden).
2.6. Western Blots. Aliquots (17.5 μL) of each clarified extract
and corresponding pellet suspension were denatured by the
addition of 5 μL of 4x NuPAGE LDS Sample Buffer (Invitro-
gen), 2 μL of 1 M dithiothreitol, followed by heating to 90◦C
for 10 minutes. The samples were centrifuged at 13,000×g
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(5 min) and the entire contents run on precast 4–12% Bis-
Tris NuPAGE minigels, using the XCell SureLock system
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. Both SeeBlue and Magimark (Invitrogen) were
used as molecular weight markers on each gel according
to package instructions. Proteins were transferred to PVDF
membranes at 65 V for 2 hours using a transfer buffer
consisting of 20 mM TRIS, 160 mM glycine, and 0.04% SDS.
The PVDF membranes were blocked on a rotary shaker
at room temperature with two different blocking buffers. A
blocking buffer consisting of 100 mM phosphate buffered
saline with 0.05% Tween, 0.01% Thimerosal, and 10% nonfat
milk was used for the FASLG, NRP1, KDR, LAMP-3, BCL-
2, CCNE2, and AKT blots. These were incubated for 10 min
before primary antibody addition. The blocking buffer used
for the EDG4, EDG2, GPC3, and TUBB blots consisted
of 25 mM Tris, 0.15 M NaCl, 0.1% Tween-20, and 0.01%
thimerosal at pH 7.4 containing 2% nonfat milk. The second
set of membranes were blocked for 1 h before addition of the
primary antibody. In both cases, the blocking buffer used for
incubation was removed before addition of fresh buffer with
the primary antibody. Primary antibodies were added at a
nominal concentration of 1 μg/mL in 10 mL of the respective
blocking buffers for FASLG, NRP1, KDR, LAMP-3, BCL-2,
CCNE2, and AKT blots, and a nominal concentration of
0.5 μg/mL in 12 mL for the EDG4, EDG2, GPC3, and TUBB
blots (except with 1% nonfat milk). Each blot was incubated
with the primary antibody overnight on a rotary shaker
at 0–4◦C. Primary antibodies consisted of affinity-purified
polyclonal antibodies against each biomarker purchased
from various sources (Table 1). Appropriate cell lysates were
used as positive controls for each of the antibodies in the
western blots (Table 1).
After overnight incubation with the primary antibody,
the blots were washed 4-5 times with their respective block-
ing buffers (without the nonfat milk). Washed blots were
placed in 4 mL of the respective blocking buffer (without
the nonfat milk) to which the appropriate antiprimary,
secondary HRP-conjugated antibody (Cell Signaling) was
added as supplied at a 1 : 1000 dilution for the FASLG, NRP1,
KDR, LAMP-3, BCL-2, CCNE2, and AKT blots and 1 : 10,000
dilution for the EDG4, EDG2, GPC3, and TUBB blots.
Blots were incubated with the HRP-conjugated secondary
antibodies for 1 h at room temperature on a rotary shaker.
Blots were again washed as described above and developed
using Supersignal West Femto substrate (Pierce, Thermo-
Fisher) following the manufacturer’s recommendations. The
chemiluminescent images were collected using a Fluorchem
SP gel imager (Alpha Innotech, San Leandro, CA). The grey
scale was inverted during postprocessing.
2.7. Sample Preparation for Immunoaffinity Techniques.
Ovarian tumor samples extracted with TD2 buffer using
the Barocycler (as described above) were diluted 1 : 10 in
ProteoSolve-TDilute (Pressure Biosciences) containing both
phosphatase and protease inhibitors (previously described)
prior to any immunoaffinity work.
2.8. Enzyme-Linked Immunosorbent Assays. The effect of
the diluted TD2 buffer on immunoassays was evaluated in
several commercial ELISA kits, including human transferrin
kit (Bethyl Laboratories, Montgomery, TX), Quantikine
MMP-2 and MMP-3 (R&D Systems, Minneapolis, MN), and
PathScan total p53 and PathScan total AKT1 (Cell Signaling,
Danvers, MA). Immunoassays were performed following
the manufacturer’s instructions and in parallel with stan-
dards reconstituted in the diluted TD2 buffer (described
above). Rate assays (change in absorbance with time) were
performed, instead of the standard single time point, to
ascertain any residual effects of the TD2 buffer components
on the amplification step of the assay (i.e., modulation of
horseradish peroxidase [HRP] enzyme kinetics or quenching
of substrate color development).
Nonlinear least squares curve fit of the antibody binding
(1) to the standards prepared in each buffer system was
used to get the apparent affinity constants (Kaff ). While the
total antigen concentration [An] is known in the standard
curve, the total antibody concentration [Ab] and the affinity
constant were determined simultaneously by nonlinear curve
fit. The one sigma error of the estimate in each fitted
parameter was determined from the Jacobian matrix.








The ovarian TD2 extracts (after 1 : 10 dilution in
ProteoSolve-TDilute) were also run in each assay to deter-
mine the effective biomarker concentrations in the extract.
Because of this dilution, the highest tissue concentration
tested was 15 mg of tissue/mL, which in a 100 μL ELISA
sample well is the equivalent of 1.5 mg of tissue.
2.9. Immunoaffinity Enrichment of Specific Biomarkers.
Antibody-conjugated PhyTips (PhyNexus, Sunnyvale, CA)
were used for all immunoaffinity enrichment experiments.
The experiments were conducted on a PhyNexus MEA robot
system (PhyNexus, Sunnyvale, CA) using deep well plates.
Each tip contained 100 μL fluidized beds of AminoLink
Resin (Pierce Protein Research, Thermo-Fisher Scientific,
Rockford, IL) conjugated to affinity-purified polyclonal anti-
transferrin antibody (Bethyl Laboratories, Montgomery, TX)
and packed in glycerol. The antibody conjugation procedure
is described below. The sample consisted of 1 mL of ovarian
tumor extract prepared in TD2 buffer and diluted (1 : 10 in
ProteoSolve-TDilute) as described above. Nonspecific goat
IgG (Equitech-Bio, Kerrville, TX) was added to the sample
(9 mg per 10 mL of diluted sample) to suppress histone
binding to the antibodies present on the bead surface [39].
Glycerol (used to pack and store the PhyTips) was found
to significantly alter flow through the PhyTips and suppress
ionization in the subsequent mass spectrometric analyses.
This glycerol was removed by washing the PhyTips with
100 mM PBS (pH 7.2) in two stages using 96-well deep well
trays (Seahorse Labware, no. S30009, 2 mL per well). The
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Table 1: Affinity-purified polyclonal antibodies used for western blots and their sources.
Biomarker Source Ab Catalog no. Control cell lysate
Lysophosphatidic acid receptor 2 (EDG4) Santa Cruz Biotechnology sc25490 BT-20
Lysophosphatidic acid receptor 1 (EDG2) Abcam ab23698 A549
CD95L, tumor necrosis factor ligand (FASLG) Cell Signaling 4233S MDA-MB-231
CD304, neurophilin-1 (NRP1) Santa Cruz Biotechnology sc7329 MDA-MB-231
CD309, vascular endothelial growth factor receptor 2 (KDR) Santa Cruz Biotechnology sc48161 MOLT-4
CD63, lysosomal-associated membrane protein 3 (LAMP-3) Santa Cruz Biotechnology sc15363 MOLT-4
Apoptosis regulator 2 (BCL2) Cell Signaling 2872 MOLT-4
Cyclin-E2, G1/S-specific (CCNE2) Strategic Diagnostics 2901.00.02 MOLT-4




RAC serine/threonine-protein kinases (pan-AKT) R&D Systems AF2055 MOLT-4
β-tubulin (TUBB) Santa Cruz Biotechnology sc9935 NIH/3T3
first stage wash consisted of four successive quick rinses in
single draw and expel cycle each of 1 mL at a 2 mL/min
flow rate (with 2 min holds at the top and bottom of each
cycle). This removed the glycerol surrounding the bead bed,
but left glycerol saturating the beads themselves. Diffusion
of the glycerol out of the pores of the beads in the second
stage required four additional washes consisting of a 0.5 mL
draw followed by 60 cycles of 0.3 mL volume at a 2 mL/min
flow rate (with 2 and 10 sec holds at the bottom and top
of each cycle). This totaled about 30 min in each 20 mL
wash volume (for 12 tips). Immediately following glycerol
removal, the tips were immersed in a trough of an 8-row
deep trough trays (Seahorse Labware, no. S30020, 32 mL per
trough) containing 10 mL of diluted tumor sample. Next,
0.5 mL of sample was drawn into each tip, and 0.3 mL was
cycled 240 times at 2 mL/min (with 2 and 10 sec holds at
the bottom and top). This totaled about 2-hour for sample
binding. Sample binding was immediately followed by a
stringency wash in 4.17 M NaCl with 83 mM NaPO4 (pH 7.2)
for 60×0.5 mL cycles at 2 mL/min (with 2 and 10 sec holds at
bottom and top). This was followed by buffer exchange into
150 mM pyridinium acetate (pH 6). Five washes in 10 mL
of pyridinium acetate in a trough (0.5 mL with 48 cycles
of 0.3 mL each at 2 mL/min with 2 and 10 sec holds at the
bottom and top of each cycle) were required to diffuse all the
salts from within the bead pores. Antigens were subsequently
eluted directly into 2 mL microfuge tubes containing 0.6 mL
of 50% aqueous acetic acid (0.5 mL draw with 30 cycles of
0.3 mL at 2 mL/min). The eluates were dried overnight in a
SpeedVac (Savant). The residual pyridium acetate is a volatile
buffer, which evaporated with the water in the SpeedVac.
2.10. Antitransferrin Antibody Conjugation to PhyTips. Cus-
tom PhyTips were purchased from PhyNexus (Sunnyvale,
CA). These were 1.1 mL volume pipette tips packed by
PhyNexus with 100 μL of AminoLink beads (ThermoFisher)
in a fluidized bed configuration. Affinity-purified, carrier-
free, goat polyclonal antitransferrin antibodies (no. A80-
128A, Bethyl Laboratories, Montgomery, TX) were dissolved
at 83 μg/mL in 100 mM PBS (pH 7.8) with 33 mM sodium
cyanoborohydride (NaCNBH3). A 0.6 mL quantity of the
antibody solution was placed in the well of a deep-well plate
for each tip. A 0.5 mL quantity of the antibody solution was
drawn into each glycerol-free PhyTips (washed as described
above) and processed for 960 cycles of 0.3 mL at 2 mL/min
(6 h). Unreacted AminoLink aldehydes were then quenched
with a 0.5 mL draw and 60 cycles of 0.3 mL each at 2 mL/min
(0.5 h) in 1 M tris(hydroxymethyl)-aminomethane chloride
(pH 7.8) with 33 mM NaCNBH3. Residual TRIS and
cyanoborohydride were removed with five washes (0.5 mL
draw and 60 cycles of 0.3 mL each) in 100 mM PBS, the last
of which contained 0.05% sodium azide. The tips were then
packed with glycerol and stored refrigerated. An average of
35 μg Ab was bound to each PhyTip, as determined by UV280
absorbance change in the conjugation solution.
2.11. MALDI-MS Analysis. Immunoaffinity-enriched trans-
ferrin from ovarian tumor extracts was identified by peptide
mass fingerprinting. The dried eluates (described above)
were dissolved in 0.1 mL of 20 mM ammonium bicarbonate
(pH 8.2), simultaneously reduced and capped by the addition
of 2 μL each of 2-vinylpyridine (50 mM in isopropanol)
and triethylphosphine (25 mM in isopropanol) at 37◦C
for 1 h, following the procedure described by Hale et al.
[40]. After capping, the eluates were digested by adding
2.5 μL of trypsin (Sequencing Grade-Modified, Promega,
Madison, WI), reconstituted at 100 μg/mL in 20 mM ammo-
nium bicarbonate, for 2 h at 37◦C. Addition of 0.11 mL
of HPLC grade acetonitrile quenched the digestion, and
the digest was evaporated overnight in a SpeedVac. The
pellet was resuspended in 25 μL of MALDI matrix (α-cyano-
4-hydroxycinnamic acid dissolved at 5 mg/mL in 50 : 50
acetonitrile : water with 0.1% trifluoroacetic acid), and 1 μL
of the digest was spotted on a stainless steel MALDI plate and
analyzed using a Q-TOF Premier (Waters, Milford, MA). The
resulting monoisotopic peptide peaks were selected using
mMass [41], and matching proteins were identified using
MASCOT to search the Swiss-Prot protein database [42].
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3. Results and Discussion
3.1. Global Protein Recovery. In order to show equivalence to
classic extraction buffers, we performed a global proteomic
analysis (2D gel electrophoresis) using separate 100 mg
aliquots of a cryogenically ground metastatic ovarian tumor
sample pool (sourced from multiple patients). Using the
Barocycler, the first aliquot was extracted in HEPES buffer
and a second processed in the TD2 buffer. The clarified
extracts were diluted to 8.6 mg of tissue/mL in denaturing
IEF buffer for 2D gel analysis. Comparison of the resulting
gels by image analysis (Figure 1) reveals few differences
in the more abundant protein species recovered. Of 585
discrete protein spots identified, 97% were common in both
position and abundance between the two gels. Only 14
protein spots were unique to the TD2 extraction buffer
gel. One spot was unique to the HEPES extraction buffer.
These 15 differences were all in less abundant proteins.
Therefore, TD2 buffer appears fully compatible with classic
gel electrophoretic methods with little alteration in recovery
of the more abundant proteins.
3.2. Recovery of Specific Proteins. Only the most abundant
proteins can be seen in Coomassie-stained gels. Thus, the
above analysis tells us little about the quantitative extraction
of membrane proteins. We, therefore, selected a number of
representative biomarkers from different protein classes for
more detailed analysis by western blots. In particular, we
were interested in determining how much protein of each
class was left behind unrecovered in the insoluble pellets. To
this end, the insoluble Barocycler pellets from each condition
tested were recovered and treated by boiling in SDS-PAGE
sample buffer. These SDS extracts of the pellets were run side
by side in western blots with the clarified extracts at similar
“effective” tissue concentrations.
Tissue extractions were performed with HEPES, TD1,
and TD2 buffers at 150 mg tissue/mL buffer concentrations.
The Barocycler extracts were centrifuged to recover an
insoluble pellet and a soluble protein extract as separate
samples. The extracts were diluted directly into 4x LDS-
PAGE sample buffer (Invitrogen, Carlsbad, CA) to an
equivalent gel loading concentration of 110 mg tissue/mL.
All the pellets were resuspended in TDilute buffer to an
equivalent concentration of 200 mg of tissue/mL to create a
fine suspension. An aliquot of this suspension was diluted
in LDS-PAGE sample buffer to an equivalent gel loading
concentration of 140 mg tissue/mL. A series of western blots
(Figure 2) were prepared from these extracts and pellets.
Each blot was probed for a different protein.
Each extract and corresponding pellet sample were
obtained from the same PULSE tube (i.e., the same tissue
preparation). Therefore, it is possible to determine the
relative abundance of each protein seen between the extract
and pellet for each buffer. However, different PULSE tubes
are used for each of the different extraction buffers tested.
Because of water condensation during the weighing of
frozen tissues, the amounts of tissue may vary between
PULSE tubes. This makes direct cross-comparison of abso-
lute protein recovery between buffers impractical. However,
recovery determinations between the clarified extract and its
corresponding pellet are possible.
Detailed descriptions of the specific proteins analyzed by
western blots (Figure 2) can be found in the Supplementary
Materials available online at doi:10.1155/2012/838630. The
salient features of these proteins are summarized in Table 2.
Key among these features are the number of transmembrane
sequences, the theoretical (sequence MW) of the protein
and any splice variants, and the reported measured MWs of
the protein, including any posttranslational modifications.
Alternate gene names are also provided to facilitate searches.
EDG2 and EDG4 are both G-protein-coupled receptors.
Two strong overlapping EDG4 bands appear in the gel with
nearly equal intensity and differing by less than 2 kDa in
weight in the cell line control (lane J) between 50 and
60 kDa. Single strong EDG4 bands are seen in all the ovarian
tumor samples at 55 kDa, except the HEPES extract (lane
B). Three weak bands are seen in the HEPES extract at 55,
56, and 57 kDa, only one of which may correlate to EDG4.
Clearly, little EDG4 is extracted into the HEPES buffer in
the Barocycler since the amount extracted from the HEPES
pellet (lane C) is in great excess to any of the bands seen in
the HEPES extract. It is also possible that all the bands seen
in this extract may be cross-reactive protein species because
the band pattern is so different from that observed in any
of the other samples. The strongest EDG4 band in both the
TD1 and TD2 extracts (lanes D and F, resp.) appears at
a slightly lower apparent molecular weight than the EDG4
band in the corresponding pellets. We note, however, that
the molecular weights for the EDG4 bands observed in the
1/3 dilution of the TD2 extract (lane H) appear at the higher
molecular weight observed for both the cell line control and
the dominant EDG4 band observed in the TD1 and TD2
pellets. Therefore, we suspect that the EDG4 protein in both
the TD1 and TD2 extracts is running at a slightly lower
molecular weight, either because the protein load in these
lanes is too high or the SDS fails to fully displace bound
membrane lipids found in the insoluble pellet fractions. An
additional weak band is seen at 56-57 kDa in the 1/3 dilution
of the TD2 pellet (lane H), but in none of the other samples,
and may be an artifact.
An EDG2 band is seen in all samples at or just below
50 kDa, including the cell line control (lane H). The protein
appears to run at a slightly higher molecular weight when
recovered with hot SDS from the Barocycler pellets than
when isolated from the Barocycler extracts. This may reflect
incomplete displacement of adsorbed lipids by SDS from
the insoluble protein found in the pellets. However, it may
also merely reflect differences in protein concentrations
between the gel lanes since the 1/3 concentration sample
of the TD2 Barocycler extract (lane H) runs closer to the
higher-molecular-weight band and appears less distorted.
The EDG2 band in the cell line control (lane J) is similarly
distorted as the other extracts. EDG2 recovery seems to
improve dramatically from the HEPES to TD buffers.
Comparison of the TD2 and TD1 buffers in this sample
shows only marginal recovery improvement.
Little or no FASLG appears to be recovered in either the
HEPES or TD1 extracts from the Barocycler (lanes B and D in




























Figure 1: 2D gel analysis of proteins extracted from the same metastatic ovarian tumor sample by (a) HEPES buffer (Gel 1) and (b) TD2
buffer (Gel 2). Each extraction was conducted for 30 pressure cycles (30,000 psi for 20 sec followed by 0 psi for 20 sec) at a concentration
of 75 mg tissue/mL of extraction buffer using the Barocycler. The samples were subsequently diluted to 8.6 mg/mL in ProteoSolve-IEF (a
denaturing IEF gel buffer) for gel analysis. Automated gel image analysis of the Coomassie-stained gels suggests that 97% of the protein spots
are shared between the two gels in position with most (74%) of the same abundance (d). One spot is uniquely found in the HEPES control,
and 14 spots are unique to the ProteoSolve-TD2 extraction.
Figure 2). FASLG is seen in high abundance in the insoluble
pellets from both of these extracts. However, nearly complete
recovery of FASLG is seen in the soluble TD2 extract with
little remaining in the insoluble pellet. Other experiments
(data not shown) suggested that FASLG recovery was variable
with TD1 buffer, but was consistently high in the TD2 buffer.
FASLG was not recovered in the extract after several attempts
with the HEPES buffer.
No evidence of the 72 kDa soluble form of NRP1 is
seen on the western blots. The 140 kDa membrane bound
form is present in all extracts (lanes B, D, and F). However,
NRP1 recovery into the soluble fraction was lowest in HEPES
buffer with most of the protein found in the HEPES pellet.
About half of the NRP1 appeared to be recovered in the
TD1 extract in this experiment. However, NRP1 recovery
in the TD1 buffer was inconsistent between trials (data not
shown). Almost complete recovery is seen in the TD2 extract
with only a trace of NRP1 left in the pellet. This result was
consistent between trials (data not shown). NRP1 was not
seen in the cell line control. It is possible that the antibody
used in these blots was reactive to a variant of the NRP1
protein that was not present in the cell line control used and
which presents an epitope that is removed in the creation of
the 72 kDa soluble form.
Both the intermediate and mature KDR proteins are
apparent in the western blot for both the cell line control
and the tumor samples at 200 kDa and 230 kDa, respectively.
Partial recovery of the more abundant mature KDR protein
is seen in HEPES extract (lane B) with most of the protein left
in the HEPES pellet (lane C). The intermediate glycosylated
form was not seen in the HEPES extract or pellet, possibly
due to its lower solubility in the HEPES buffer than either the
TD1 or TD2 buffers. The aqueous solubility of the mature
form is expected to be greater due to the higher level of
glycosylation. Most of the intermediate glycosylated form
appears to be extracted into both the TD1 and TD2 buffers
(lanes D and F) with apparently little left in either pellet
(lanes E and G). At least some of the more abundant mature
form (230 kDa) was seen in all the extracts (lanes B, D, and F,
Figure 2) and both the HEPES and TD1 pellets (lanes C and
E, Figure 2). The best relative KDR extraction was observed
with the TD2 buffer (lanes F and G, Figure 2).
8 International Journal of Proteomics






























Figure 2: A series of western blots for various membrane, nuclear,
and cytosolic proteins (Table 2) extracted from metastatic ovarian
tumor samples. The extracts were prepared using 3 different
extraction buffers (lane B = HEPES buffer extract, lane D = TD1
buffer extract, and lane F = TD2 buffer extract). Lane H is a
duplicate of lane F at 1/3 the protein loading. The corresponding
insoluble proteins trapped in the pellets recovered after each
extraction are also shown in the adjacent lanes (lane C = HEPES
pellet, lane E = TD1 pellet, and lane G = TD2 pellet). Either a
purified recombinant protein control (lane I) or a human cell line
extract control (lane J) was used in each blot (both were used for
EDG4, NRP1, and KDR). Lanes A (see blue, Invitrogen) and K
(Magic Mark, Invitrogen) are molecular weight markers. Lane A is
only visualized in visible light, not in the chemiluminescent images
shown. Both of these markers (see blue from a white light image
not shown) were used to determine the molecular weights shown
(on the right hand side). Gaps between lanes are provided only for
alignment purposes, and the lanes are from the same gels.
Two bands at 58 kDa and 73 kDa are seen for the LAMP-
3 protein in the western blot (Figure 2). It is not clear if the
upper band is a cross-reactive antigen or a hyperglycosylated
version of the protein, but it is found in both the control
cell line (lane J, Figure 2) and all tumor extracts. Little of
either molecular weight species are seen in any of the pellets,
except for a trace of the 73 kDa species in the TD1 pellet.
These high apparent recoveries, independent of extraction
buffer used, may be due to the hyperglycosylation of this
protein, particularly present between the transmembrane
helixes. LAMP-3 is found in all the extracts but appears
to be in low total abundance overall in the tumor samples
because long chemiluminescent substrate exposure times
were required to visualize LAMP-3 compared to the other
biomarkers tested. Reblotting with higher primary antibody
titers did not appear to improve the signal strength (data not
shown).
BCL2 is a single-pass apoptosis regulator predominantly
found in the outer mitochondrial membrane, but also seen
in the nuclear, and endoplasmic reticulum membranes.
Recombinant human BCL2 (the first 218 amino acids and
nonglycosylated) is used as the antibody control. This
truncated recombinant form runs at 24 kDa. Native BCL2
from the tumor samples is seen at 30 kDa [49]. BCL2
recovery was good, but not complete, in all buffers tested,
with the best apparent recovery in HEPES buffer. There
was no apparent difference in recoveries between the TD1
and TD2 buffers. BCL2 is found in mitochondria. However,
because mitochondria are not expected to pellet at the
13,000×g used in this experiment [33], it is possible that
BCL2 seen in the HEPES extract is actually recovered from
intact suspended mitochondria after heating in SDS-PAGE
sample buffer. The same may be true of the other buffers,
making it difficult to differentiate BCL2 recovery among the
Barocycler extraction buffers.
In our work, two CCNE2 bands are seen in the western
blot of the cell line control and tumor samples (Figure 2), a
dominant band at 45 kDa and a minor band at 47 kDa. These
bands probably correspond to the long and short isoforms.
As CCNE2 is not a membrane-bound protein, we would
expect recoveries to be good in all the buffer systems tested.
However, some of the dominant 45 kDa protein remains
in the HEPES pellet (lane C). A trace amount is also seen
in the TD1 pellet (lane E, Figure 2). These bands might
be explained from residual extract present in the unwashed
pellets. Extraction appears to be nearly quantitative with the
TD2 buffer (lanes F and G, Figure 2). These results could
also suggest that one of the components of the TD1 and TD2
buffers may be assisting Barocycler disruption of the nuclear
membrane.
When the western blot from our work is probed with a C-
terminal-specific GPC3 antibody (i.e., raised against amino
acids 303–464) [52], a single strong band is seen in the gel
at 30 kDa for all the tumor and cell line samples. The GPC3
protein is lipid anchored to the cell membrane in this C-
terminal region. Several splice, or posttranslationally edited,
variants are noted in the literature. None of these proteins
is extracted into HEPES buffer (lane B, Figure 2). A small
amount (≈10%) appears to be extracted into TD1 in the
sample shown (lanes D and E, Figure 2). About 75% appears
to be extracted into TD2 buffer (lanes F and G, Figure 2).
This 30 kDa protein is also seen in the cell line control. No
other bands are seen in the blot probed with the C-terminal-
specific antibody.
When the blot is stripped and reprobed with an antibody
specific to the N-terminal GPC3 region [53], however, a
single band is seen near 80 kDa in the cell line control (lane
J, Figure 2). The 30 kDa fragment is not detected with the N-
terminal-specific primary antibody. No corresponding bands
in the 60 to 80 kDa region are seen in the gel. Since the
mature protein is exported, it would normally be carried
away from the tumor site in the blood; therefore, little
mature protein is expected to remain in the solid tumor.
These results suggest that the 30 kDa fragment may be
the lipid-anchored C-terminus (postmodification), which is
only recovered in the TD1 and TD2 buffers and that the
80 kDa band is the full-length protein with its lipid-anchored
C-terminus intact.
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β-tubulin 0 TUBB [55] 50 kDa 50 kDa [56] 95%
AKT is seen at 60 kDa in the western blot, as determined
from the recombinant control (lane I, Figure 2). The second
band seen in the recombinant human AKT control sample
(at 62 kDa, lane I, Figure 2) is attributed to incomplete
cleavage of the His6 tag used in the purification of this fusion
protein. AKT recoveries are high in all the buffers tested,
which would be expected for a soluble cytosolic protein, with
no apparent differences between the buffers tested.
While TUBB is generally a cytosolic protein, it spon-
taneously forms dimers with alpha-tubulin (TUBA) and is
always in dynamic equilibrium between soluble a/b-dimers
and polymerized microtubules, which can be insoluble
depending on their size [57]. A single strong band at 50 kDa
is seen in all lanes of the TUBB western blot (Figure 2). Based
on the relative chemiluminescent intensities, about 50% of
the TUBB is recovered in the HEPES extract (comparison
of lanes B and C, Figure 2). TD1 appears to extract more
than 80% of the TUBB present in the sample (comparison of
lanes D and E, Figure 2). TD2 extracts better than 90% of all
the TUBB present. In separate time course experiments (data
not shown), we have shown that purified bovine tubulin
(Cytoskeleton, Denver, CO) remains soluble at 1 mg/mL
in TD1 buffer but polymerizes and precipitates nearly
quantitatively within 24 hours in 20 mM HEPES buffer.
Therefore, we believe that the lower apparent recovery of
TUBB in the HEPES buffer is due to microtubule formation
and precipitation in this extract.
3.3. Impact of Barocycler and Cryogenic Grinding. Several
initial attempts to process diced (unground) metastatic
ovarian tumor tissue through the Barocycler with the same
extraction buffers did not produce good yields, even for
cytosolic proteins (data not shown). Therefore, cryogenic
grinding prior to Barocycler extraction appears to be nec-
essary. We speculate that the higher surface-to-volume ratio
of the ground tissue allows for better access of the extraction
buffer and shorter diffusional paths for the extracted proteins
during pressure cycling. Furthermore, as cited above, results
10 International Journal of Proteomics
with the TD1 buffer proved inconsistent from sample to
sample. Some samples yielded small friable pellets and had
good protein yields, and others appeared to leave a large
sticky pellet after pressure cycling. These latter samples
exhibited poor protein recovery. The addition of a dispersion
aid (TD2 buffer) resulted in vastly improved sample-to-
sample reproducibility. Furthermore, no appreciable protein
could be extracted from ground tumor samples heated at
95◦C for 1 h in either the TD1 or TD2 buffers in the absence
of pressure cycling. When SDS was added to these samples,
in the form of SDS-PAGE sample buffer (Invitrogen), protein
was subsequently recovered on additional heating (data
not shown). This demonstrates that pressure cycling is an
integral part of the membrane protein extraction process
with the ProteoSolve-TD buffers and that the buffers alone
do not act as detergents.
3.4. Enzyme-Linked Immunosorbent Assays. Several commer-
cial sandwich ELISA kits (transferrin, MMP2, MMP3, AKT1,
VEGF, and sVEGF R2) were used to determine the effect
of the TD2 extraction buffer on subsequent immunoaffinity
work. In each case, one vial of antigen standards was
reconstituted as prescribed in the manufacturer’s instruc-
tions, and a second vial was reconstituted using the TD2
buffer diluted 1 : 10 by volume in ProteoSolve-TDilute (at
pH 7.5). Otherwise, the kits were run as prescribed by
the manufacturer with the exception that rate assays were
performed to determine any residual effects of the TD2
buffer on the reporter (horseradish peroxidase) activity
or substrate color development. The resulting standard
curves are presented in Figure 3. The small differences in
affinity constants between the buffers used are within the
experimental error of the serial dilutions and the curve
fitting. Furthermore, there was no consistent trend with Kaff
being either slightly higher or lower, depending on the assay,
and generally within the expected preparation variation of
the standards. The lone exception was the VEGF assay, for
which no assay response is seen for the recombinant human
VEGF165 standard reconstituted in the diluted TD2 buffer.
Either this standard is not soluble or stable in the TD2 buffer,
or the buffer induces a change in the epitope recognized by
the ELISA antibodies. Other than the anomalous VEGF assay
results, these data suggest that the TD2 extraction buffer
has no significant affect on antibody affinity or antigenicity
of the recovered proteins. Presumably the kit buffers had
been optimized by the manufacturers for each assay. The
TD2 extraction buffer was used without optimization in all
the assays. We expect, therefore, that better results may be
obtained in each assay with further diluent optimization.
The resultant antigen concentrations in the metastatic
ovarian tumor TD2 extracts were also determined in these
assays and are summarized in Table 3. Holotransferrin (holo-
Tf) is a surrogate marker for the blood or serum content of
the tumor sample. Serum Tf concentrations are reported to
be in the range of 2.9–4.0×106 ng/mL [58, 59]. Assuming all
of the serum Tf is recovered in the TD2 extract, we estimate
0.5 × 106 ng Tf per g of tissue, suggesting that the average
blood/serum content of the frozen metastatic tumor samples
is around 15%. Matrix metalloproteinase 2 (MMP2) is below
the detection limits of the ELISA (i.e., <70 ng per g of tissue).
Matrix metalloproteinase 3 (MMP3) is detectable above
background at the highest extract concentration used, but is
below the quantitation limits of the assay (i.e., ≤7 ng per g
of tissue. No references to the tumor tissue concentrations
of these proteins could be found, so recovery could not
be determined. AKT1 is a cytosolic protein for which the
western blots (Figure 2) suggest nearly quantitative recovery
with the TD2 buffer. The total AKT1 concentrations were
determined to be about 20 μg/g of tissue, determined from
the single ELISA sample tested. VEGF R2 (also known as
KDR) is a heavily glycosylated membrane protein. The glyco-
sylated N-terminal domain, which is often cleaved, becomes
a plasma-soluble biomarker species (sVEGF R2). Assuming
that the antibodies towards sVEGF R2 will crossreact with
the membrane bound version, we thought this ELISA kit
might provide a more quantitative measurement of the
amount of the membrane protein recovered than the western
blot (Figure 2), which suggested high recovery efficiency in
the TD2 extraction buffer. Polanski and Anderson report
the plasma concentration of sVEGF R2 to be 15 ng/mL
[59]. The measured tissue concentration of VEGF R2 is
1 ± 0.1 ng/g of tissue, which is about twice as high as that
expected for sVEGF R2 in the 15% blood contamination
of the tissue sample. This translates to an expected sVEGF
R2 concentration of 0.5 ng/g of tissue. However, the amount
of sVEGF R2 measured for the HEPES Barocycler extract
was indistinguishable from that seen in the TD2 Barocycler
extract. Yet, KDR (VEGF R2) recovery in HEPES buffer was
poor compared to that observed in the TD2 extraction buffer
(Figure 2). Possible explanations are that the ELISA assay is
truly specific to the soluble form of this protein, VEGF R2
recovery differs negligibly between the different extraction
buffers (i.e., the western blot results are not quantitative), or
the amount of membrane-bound VEGF R2 is low relative to
that of the sVEGF R2 in the patients’ plasma.
3.5. Immunoaffinity Enrichment/MALDI-MS. Antitransfer-
rin PhyTips were prepared as described in the methods.
These were used to recover and enrich transferrin protein
from the TD2 ovarian tumor extract. ELISA data indicate
that the extract contains 80 μg of transferrin (Table 3). Digest
controls prepared with different concentrations of purified
buffer-free apotransferrin (Sigma-Aldrich) suggested a limit
of detection of about 4 ng of transferrin in a single MALDI-
MS spot (1 μL of sample matrix) for protein identification
using peptide mapping. No improvement in sequence cov-
erage was seen above 1 μg of apotransferrin in a 1 μL spot.
Of the 34 peaks found in the spectrum and submitted to
a MASCOT search, 24 mapped to peptides from human
transferrin, which was the top-ranked protein (score of 280).
Sequence coverage was 36% (Figure 4).
4. Conclusions
4.1. Global Protein Recovery and Analysis. Global proteomic
comparison between the HEPES and TD2 extracts (Figure 1)
shows few differences from among the higher-abundance
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Figure 3: No significant effect of the TD2 buffer was seen in either the rate of color development from the HRP conjugate or antigen affinity
in commercial ELISA kits for (a) total human transferrin (Tf), (b and c) total human matrix metalloprotease 2 (MMP2) or 3 (MMP3), (d)
total human V-akt murine thymoma viral oncogene homolog 1 (AKT1), or (e) soluble vascular endothelial growth factor receptor (sVEGFR).
Apparent affinity constants (±one standard deviation) for separate serial dilutions for the kit standards are shown for each ELISA for both
the recommended kit diluent and TD2 buffers. (Standard deviations are determined by partitioning the error of the estimate across the fitted
parameters using the Jacobian matrix. In ELISA assays lacking experimental data defining the upper asymptotic limits of quantitation (e.g.,
VEGF R2 assay of Figure 3), this method produces very large errors when fitting the data with a nonlinear equation (1)).
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Table 3: The concentrations of various protein biomarkers
extracted from mixed metastatic ovarian tumors obtained from
the omenta of various patients during surgical debulking as
measured by ELISA. Proteins were extracted from the cryogenically
ground tumor samples using a Barocycler with TD2 Buffer. The
concentrations (± one standard deviation) of each biomarker are
determined from the extract contained using the ELISA assays
described in Figure 3 and extrapolated to that present in the tumor
assuming 100% recovery. Transferrin was used as a ubiquitous
control protein, which is indicative of the serum content of the
sample. Some biomarkers were below the detection limits of the







Holo-Tf 80,000 ± 40,000 5× 106 ± 3× 106
MMP2 BDL (<10) BDL (<70)
MMP3∗ ≈1 ≈7
AKT1 40 (single determinant) 20× 103
VEGF R2/sVEGF R2 0.2 (only 2 replicates) 1± 0.1
BDL: below detection limits (assay detection limits).
∗Measurements were below the quantitation limits of the assay.
proteins recovered from the sample. Some 2,000 different
proteins have titers greater than 5× 104 copies in the average
mammalian cell [60]. The cellular titers of many cellular
receptor (membrane) proteins are reported to be in the
range of 103–105 copies per cell, by comparison [61]. The
same dynamic range issues that plague global analysis of
the plasma proteome [62] also plague cellular proteomic
analysis. With the limited dynamic range for a Coomassie-
stained gel [63], we may not see lower-abundance membrane
proteins in such a global proteomic analysis. Nonetheless, the
2D gel data are important in that they show virtually that
all the same proteins are recovered in the TD2 buffer as are
recovered in a more standard aqueous buffer and in similar
abundance. Furthermore, the ProteoSolve-TD buffers do not
affect either the isoelectric focusing or SDS-PAGE separation
coordinates of any proteins. Therefore, we conclude that the
ProteoSolve-TD buffers are fully compatible with this time-
honored global proteomic technique.
4.2. Membrane Protein Recovery. The western blots (Fig-
ure 2) provide definitive evidence for the recovery of seven-
different integral membrane proteins. EDG2 and EDG4,
both seven transmembrane G-protein-coupled receptors,
appeared to be recovered well in the TD2 buffer system
and virtually not at all in the HEPES control buffer. EDG4
recovery, however, may not have been quantitative, but this
is confounded by apparent cross-reactivity of the primary
antibody with proteins of similar size. FASLG, NRP1,
and KDR (VEGF R2) proteins, all single transmembrane
proteins, were nearly quantitatively recovered in the TD2
buffer but also showed partial recovery in the HEPES control
buffer. LAMP-3, an apparently low-abundance protein with
four-transmembrane sequences, appeared to be recovered
in good yield in all the extraction buffers. LAMP-3 is
highly glycosylated (particularly between the transmem-
brane helixes), potentially improving its aqueous solubility.
Neither overnight incubation or boiling of the tissue samples
in the ProteoSolve-TD buffers showed any significant trans-
membrane protein recovery (data not shown), suggesting
that extraction of the membrane proteins was primarily due
to the pressure cycling process. These observations support
a PCT mechanism (a mechanistic discussion can be found
in the Supporting Information) in which the pressure cycle
itself is primarily responsible for disruption of the lipid
membranes and exclusion of the membrane proteins. The
data further suggest that the ProteoSolve-TD buffers need
only to support the solubility of the pressure-extracted
membrane proteins when the sample is returned to ambient
conditions.
GPC3 is a lipid-anchored protein. What appears to be
a 30 kDa C-terminal domain, which contains the lipid-
anchor, only appears to be recovered in the TD1 and
TD2 buffers (Figure 2). The soluble 65 kDa mature GPC3
protein, resulting from cleavage of the C-terminal, lipid-
anchored domain, was not seen in any of the samples.
BCL2, a mitochondrial protein with a single-transmembrane
sequence, was the only protein to show better recovery in the
HEPES buffer than either TD1 or TD2 buffers. We believe
that this was caused by the failure to pellet mitochondria
during the centrifugation step (13,000×g). Centrifugation at
52,000×g is normally required to pellet free mitochondria
[33]. If mitochondria were left suspended in the extracts,
then BCL2 would have been liberated from the membranes
upon sample preparation for SDS-PAGE (i.e., boiling in SDS
sample buffer). Higher recoveries of TUBB were evident in
both the TD1 and TD2 buffers compared to the HEPES
control. We believe this result is due to improved solubility
of tubulin microtubules in the TD buffers over that in
HEPES control. By contrast, the soluble protein controls (i.e.,
CCNE2, AKT, and TUBB) appeared to be well recovered in
all of the Barocycler buffers.
4.3. Compatibility with Immunoaffinity Techniques. Of par-
ticular clinical interest is that the TD extraction buffers
appear to stabilize membrane proteins in an aqueous envi-
ronment that is compatible with subsequent immunoaffinity
techniques (e.g., immunosorbent assays or immunoaffinity
enrichment). With performance data from five different
ELISAs (Figure 3), we can say with good confidence that
the TD buffer system can have negligible effect on antibody
affinity constants. Nor does the TD buffer system affect
subsequent activity of the final ELISA amplification reaction
(at least with the commonly used HRP enzyme). Only a
single assay (VEGF) failed with the TD2 extraction buffer
system. We believe this may be due to a structural difference
in the VEGF epitope in the ProteoSolve-TD buffer system.
This might be overcome by the selection of alternative
capture or reporter antibodies for the ELISA, but was
untried.
Unlike the western blot data (Figure 2), we found no
significant difference between sVEGF R2/VEGF R2 titers
(by ELISA) between the HEPES and TD2 extraction buffer
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systems (Table 2). While membrane-bound VEGF R2 (KDR)
can be distinguished from sVEGF R2 in a western blot
(based on molecular weight differences), these can only be
distinguished in an ELISA based on the specificity of the
antibodies, which are unknown in the kit used. This ELISA
was designed for sVEGF R2 (a plasma marker) and may
not be cross-reactive with the membrane-bound version.
However, the VEGF R2/sVEGF R2 tissue titers determined
(1 ± 0.1 ng/g of tissue) were double the sVEGF R2 titer
expected to be present in the entrained blood in the sample
[59]. AKT1 (a soluble cytoplasmic protein) was found to be
present in the patients’ samples at a titer of 20 μg/g of tissue.
We note that both the MMP2 and MMP3 were below
the limits of detection or quantitation of the ELISAs used
in this study. It seems likely that many cellular proteins
of clinical relevance may be similarly too dilute for direct
measurement in the small (≤0.2 mL) well volumes of
standard ELISA microwell plates. Therefore, we investi-
gated the use of immunoaffinity enrichment to concentrate
lower-abundance biomarkers from larger sample volumes
for subsequent analysis. Subsequent mass spectrometric
analysis was successfully used to confirm the identity of
immunoaffinity-enriched transferrin (Figure 4). Not only
does this enrichment experiment demonstrate the affinity
and avidity of the TUBB antibody in TD2 buffer, but it
also shows that none of the buffer components survive the
enrichment process to interfere with enzymatic digestion of
the sample, peptide ionization (e.g., ion suppression), or
mass spectral analysis (e.g., adduct formation).
4.4. Compatibility with Mass Spectrometry. Immunoaffinity
enrichment followed by direct mass spectrometric determi-
nation of the mass of the intact protein to identify possible
clinically relevant isoforms was pioneered by Nelson et al.
[64] and has been adapted in our laboratory for biomarker
validation. While we illustrate this method with a single
protein (Tf) to illustrate the method in this paper, however,
we have applied it to enrich 33 different biomarkers from the
same ovarian tumor samples (data not shown).
As mentioned previously, the TD1 and TD2 buffers
are fully compatible with the common protein label-
ing chemistries (data not provided). We have applied
the described immunoaffinity/MS method using isotope-
differentiated binding energy shift tags in our laboratory
(data not shown) [65]. This intact protein capture approach
allows the detection of novel protein isoforms (either
sequence variants or posttranslational modifications) that
may be lost in other biomarker validation methods such as
multireaction monitoring (MRM) [66] or the use of stable
isotope standards with antipeptide antibody enrichment
(SISCAPA) [67].
Many solid tumors consist primarily of compact epithe-
lial cells and connective tissue, which can be particularly
recalcitrant to protein extraction. We note that the solid
metastatic ovarian tumors used in this study had to be
cryogenically ground to a fine powder before protein extrac-
tion proved effective. A video of the sample preparation















Figure 4: The 36% mass spectrometric sequence coverage (under-
lined) from a tryptic digest of immunoaffinity-enriched transferrin
contained in a Barocycler TD2 extract of metastatic ovarian tumor
tissue.
note that the results were variable with the TD1 buffer, but
with the addition of the dispersion they aid to create the
TD2 buffer, and this recovery variability was eliminated.
We suspect that other softer tissues (e.g., liver) or harvested
cell lines may be processed via pressure cycling technology
with either the TD1 or TD2 buffers and likely will not
require prior cryogenic grinding. Pressure cycling technology
combined with the commercial ProtoSolve-TD extraction
buffers appears to offer a new approach for protein, partic-
ularly membrane protein, extraction from tissues in a format
suitable for subsequent clinical immunoaffinity methods and
classic proteomic analyses.
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